Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for ZOE.DE and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ZOE.DE and 80,000+ other tickers.
See exactly how ZOE.DE's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ZOE.DE and 80,000+ other tickers.
Zoetis Inc. is a global enterprise dedicated to the research, development, production, and marketing of a broad spectrum of animal health products. Operating both within the United States and globally, the company primarily serves a diverse range of animals, including major livestock categories such as cattle, swine, poultry, fish, and sheep, alongside companion animals like dogs, cats, and horses. Their extensive portfolio features various solutions, including biological vaccines engineered to prevent ailments of the respiratory, gastrointestinal, and reproductive systems, or to stimulate…
No recent news available.